LungLifeAI Logo

Early detection

is key

LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.

Our purpose
is simple

Featured News

February 27, 2023

Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

27 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
• Read More
February 20, 2023

Preliminary audited results for year ended 31 December 2022

20 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2022  LungLife to report financial results for full-year 2022 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2022. Summary and Highlights […]
• Read More
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down